Pancreatic Cancer Research

ResearcherGerman Cancer Research CenterActive in the last 2 years

Chiara Falcomatà

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0001-9269-2582; OpenAlex author ID A5074432798. Sources: OpenAlex.

Their work

Papers
12 (first author 1, last author 1)
Trials
0
Grants
0
Labs led
0
Collaborators
86
Papers, trials and grants by year

2021: 2 papers · 2022: 3 papers · 2023: 3 papers · 2024: 1 paper · 2025: none · 2026: 3 papers

Papers 12

  1. Pancreatic ductal adenocarcinoma: The Vision of Heracles. Co-author DOI 10.1016/j.ccell.2026.07.014↗
  2. A serpin-myeloid axis in pancreatic cancer heterogeneity and immune evasion. Co-author DOI 10.1038/s41586-026-11002-8↗
  3. Cross-species single-cell atlases chart progression, therapy-driven remodelling and immune evasion in pancreatic cancer Co-author DOI 10.64898/2026.03.19.712924↗
  4. A Novel AMPK Inhibitor Sensitizes Pancreatic Cancer Cells to Ferroptosis Induction. Co-author DOI 10.1002/advs.202307695↗
  5. Cell-selective proteomics segregates pancreatic cancer subtypes by extracellular proteins in tumors and circulation. Co-author DOI 10.1038/s41467-023-38171-8↗
  6. Single-cell profiling to explore pancreatic cancer heterogeneity, plasticity and response to therapy. First author DOI 10.1038/s43018-023-00526-x↗
  7. Context-Specific Determinants of the Immunosuppressive Tumor Microenvironment in Pancreatic Cancer. Co-author DOI 10.1158/2159-8290.cd-22-0876↗
  8. AP1/Fra1 confers resistance to MAPK cascade inhibition in pancreatic cancer. Co-author DOI 10.1007/s00018-022-04638-y↗
  9. Selective multi-kinase inhibition sensitizes mesenchymal pancreatic cancer to immune checkpoint blockade by remodeling the tumor microenvironment. Co-author DOI 10.1038/s43018-021-00326-1↗
  10. Syngeneic Mouse Orthotopic Allografts to Model Pancreatic Cancer. Last author DOI 10.3791/64253↗
  11. New Insights Into Pancreatic Cancer: Notes from a Virtual Meeting. Co-author DOI 10.1053/j.gastro.2021.04.082↗
  12. Pancreatic cancer intrinsic PI3Kα activity accelerates metastasis and rewires macrophage component. Co-author DOI 10.15252/emmm.202013502↗

Closest collaborators

The 25 strongest of 86 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Dieter Saur · 11 shared papers, 2021–2026 · strength 1.79
  2. Roland Rad · 7 shared papers, 2022–2026 · strength 1.22
  3. Stefanie Bärthel · 6 shared papers, 2022–2026 · strength 1.15
  4. Günter Schneider · 6 shared papers, 2021–2026 · strength 0.88
  5. Christian Schneeweis · 4 shared papers, 2022–2026 · strength 0.57
  6. Maximilian Reichert · 4 shared papers, 2021–2024 · strength 0.45
  7. Elisabeth Heßmann · 3 shared papers, 2021–2024 · strength 0.35
  8. Daniele Lucarelli · 2 shared papers, 2022–2026 · strength 0.33
  9. Constantin Schmitt · 2 shared papers, 2022 · strength 0.32
  10. Marina Pasca di Magliano · 2 shared papers, 2021–2026 · strength 0.28
  11. Jonathan J. Swietlik · 2 shared papers, 2022–2023 · strength 0.27
  12. Felix Meissner · 2 shared papers, 2022–2023 · strength 0.27
  13. Marian Grade · 2 shared papers, 2022–2024 · strength 0.26
  14. Lukas Krauß · 2 shared papers, 2022–2024 · strength 0.26
  15. Carolin Schneider · 2 shared papers, 2022–2024 · strength 0.26
  16. Matthias Wirth · 2 shared papers, 2022–2024 · strength 0.26
  17. Miriam Merad · 1 shared paper, 2026 · strength 0.26
  18. Brian D Brown · 1 shared paper, 2026 · strength 0.26
  19. Sebastian Rune Nielsen · 1 shared paper, 2026 · strength 0.26
  20. Bernhard Küster · 2 shared papers, 2022–2024 · strength 0.24
  21. Volker Ellenrieder · 2 shared papers, 2021–2024 · strength 0.23
  22. William L. Hwang · 1 shared paper, 2026 · strength 0.21
  23. Dennis H. Gong · 1 shared paper, 2026 · strength 0.21
  24. Pilhan Kim · 1 shared paper, 2026 · strength 0.19
  25. Marina Lesina · 1 shared paper, 2026 · strength 0.19

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.